Objective:To compare the use of the aromatase inhibitor, letrozole, in conjunction with follicle-stimulating hormone (FSH) injection, and FSH alone for controlled ovarian hyperstimulation (COH) in patients with polycystic ovarian syndrome (PCOS) or ovulatory infertility.
Methods:This nonrandomized study included two study groups: 26 patients with PCOS and 63 with ovulatory infertility (unexplained infertility [41 patients], male factor infertility [17 patients], and endometriosis [5 patients]), who received letrozole in addition to FSH; and two control groups: 46 PCOS patients and 308 with ovulatory infertility (unexplained infertility [250 patients], male factor infertility [42 patients], and endometriosis [16 patients], who received FSH only. All patients had intrauterine insemination (IUI). Main outcome measures included dose of FSH used per cycle, number of preovulatory follicles greater than 16 mm in diameter, cancellation rate, and pregnancy rate.
Results:The FSH dose required for ovarian stimulation was significantly lower when letrozole was used in both study groups comparedto the control groups without a significant difference in number of follicles greater than 16 mm. IUI cancellation rate was significantly lower with letrozole treatment in PCOS patients. In women with PCOS, clinical pregnancy rate per completed IUI cycle was 26.5% in the letrozole plus FSH group versus 18.5% in the FSH-only group. In ovulatory infertility patients, the pregnancy rate was similar in both study and control groups (11%).
Conclusion:We believe that inhibition of estrogen synthesis by aromatase inhibition will release the estrogenic negative feedback, resulting in an increase in endogenous FSH secretion. Moreover, by inhibiting conversion of androgens into estrogens, accumulating androgens may increase follicular sensitivity to FSH. Such a protocol has the potential to lower FSH treatment cost and may improve response for low responders who require high FSH doses during ovarian stimulation.
1. Farley TMM, Besley FH. The prevalence and etiology of infertility. In: Biological components of fertility. Proceedings of the African Population Conference, Dakar, Senegal, Vol 1. Laege, Belgium: International Union for the Scientific Study of Population, 1988:2.1.15-2.1.30.
2.
2. Templeton A. Infertility-epidemiology, aetiology and effective management. Health Bull (Edinb)1995;53:294-298.
3.
3. Hull M, Glazener C, Kelly NJ, et al. Population study of causes, treatment, and outcome of infertility. BMJ1985;291:1693-1697.
4.
4. Templeton A, Fraser C, Thompson B. The epidemiology of infertility in Aberdeen. BMJ1990;301:148-152.
5.
5. Snick HKA, Snick TS, Evers JLH, Collins JA. The spontaneous pregnancy prognosis in untreated subfertile couples: The Walcheren primary care study. Hum Reprod1997;12:1582-1588.
6.
6. Cahill DJ, Wardle PG. Management of infertilityEMJ2002;325:28-32.
7.
7. Franks S: Polycystic ovary syndrome. N Engl J Med1995;333:853-861.
8.
8. Guzick DS, Carson SA, Coutifaris C, et al. Efficacy of superovulation and intrauterine insemination in the treatment of infertility. N Engl J Med1999;340:177-183.
9.
9. Melis GB, Paoletti AM, Strigini F, et al. Pharmacologic induction of multiple follicular development improves the success rate of artificial insemination with husband's semen in couples with male-related or unexplained infertility. Fertil Steril1987;47:441-445.
10.
10. Dodson WC, Whitesides DB, Hughes CL, et al. Superovulation with intrauterine insemination in the treatment of infertility: A possible alternative to gamete intrafallopian transferred in vitro fertilization. Fertil Steril1987;48:441-445.
11.
11. Serhal PF, Katz M, Little V, Woronowski H. Unexplained infertility: The value of Pergonal superovulation combined with intrauterine insemination. Fertil Steril1988;49:602-606.
12.
12. Fioretti P, Paoletti AM, Strigini F, et al. Induction of multiple follicular development as a therapy for unexplained or male-related infertility. Gynecol Endocrinol1989;3:45-53.
13.
13. Melis GB, Strigni F, Mais V, et al. Critical reappraisal of the clinical effectiveness of different methods of assisted fertilization. J Endocrinol Invest1990;13:263-274.
14.
14. Kemmann E, Bohrer M, Shelden R, et al. Active ovulation management increases the monthly probability of pregnancy occurrence in ovulatory women who receive intrauterineinsemination. Fertil Steril1987;48:916-920.
15.
15. Hughes EG. The effectiveness of ovulation induction and intrauterine insemination in the treatment of persistent infertility: A meta-analysis. Hum Reprod1997;12:1865-1872.
16.
16. Sunde A, Kahn JA, Molne K. Intrauterine insemination: A European collaborative report. Hum Reprod1988;2:69-73.
17.
17. Dodson WC, Haney AF. Controlled ovarian hyperstimulation and intrauterine insemination for treatment of infertility. Fertil Steril1991;55:457-467.
18.
18. Peterson CM, Hatasaka HH, Jones KP, et al. Ovulation induction with gonadotrophins and intrauterine insemination compared with in vitro fertilization and no therapy: A prospective, nonrandomized, cohort study and meta-analysis. Fertil Steril1994;62:535-544.
19.
19. Brzechffa PR, Daneshmand S, Buyalos RP. Sequential clomiphene citrate and human menopausal gonadotrophin with intrauterine insemination: The effect of patient age on clinical outcome. Hum Reprod1998;13:2110-2114.
20.
20. Cohlen BJ, te Velde ER, van Kooij RJ, et al. Controlled ovarian hyperstimulation and intrauterine insemination for treating male subfertility: A controlled study. Hum Reprod1998;13:1553-1558.
21.
21. Fisch P, Casper RF, Brown SE, et al. Unexplained infertility: Evaluation of treatment with clomiphene citrate, human chorionic gonadotrophin or in vitro fertilization. Fertil Steril1989;51:828-833.
22.
22. Guzick DS, Sullivan MW, Adamson GD, et al. Efficacy of treatment for unexplained infertility. Fertil Steril1998;70;207-213.
23.
23. The ESHRE Capri Workshop: Female infertility: Treatment options for complicated cases. Hum Reprod1997;12:1191-1196.
24.
24. The ESHRE Capri Workshop: Infertility revisited: The state of the art today and tomorrow. Hum Reprod1996;11:1779-1807.
25.
25. Fluker MR, Urman B, Mackinnon M, et al. Exogenous gonadotropin therapy in World Health Organization groups I and II ovulatory disorders. Obstet Gynecol1994;83:189-196.
26.
26. Mitwally MFM, Casper RF. Use of aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril2001;75:305-309.
27.
27. Zawadzki JK, Dunaif A. Diagnostic criteria for Polycystic ovary syndrome: Towards a rational approach. In: Dunaif A, Givens JR, Haseltine F, Merriam GR, eds. Polycystic ovary syndrome. Boston: Blackwell, 1992:377-384.
28.
28. Dickey RP, Olar TT, Taylor SN, et al. Sequential clomiphene citrate and human menopausal gonadotrophin for ovulation induction: Comparison to clomiphene citrate alone and human menopausal gonadotrophin alone. Hum Reprod1993;8:56-59.
29.
29. Kemman E, Jones JR. Sequential clomiphene citrate-menotropin therapy for induction or enhancement of ovulation. Fertil Steril1983;39:772-779.
30.
30. Rose BI. A conservative, low-cost superovulation regimen. Int J Fertil1992;37:339-342.
31.
31. Gonen Y, Casper RF. Sonographic determination of an adverse effect of clomiphene citrate on endometrial growth. Hum Reprod1990;5:670-674.
32.
32. Nelson LM, Hershlag A, Kurl RS, Hall JL, Stillman RJ. Clomiphene citrate directly impairs endometrial receptivity in the mouse. Fertil Steril1990;53:727-731.
33.
33. Li TC, Warren MA, Murphy C, Sargeant S, Cooke ID. A prospective, randomised, cross- over study comparing the effects of clomisphene citrate and cyclofenil on endometrial morphology in the luteal phase of normal fertile women. Br J Obstet Gynaecol1992;99:1008-1013.
34.
34. Randall JM, Templeton A. Cervical mucus score and in vitro sperm mucus interaction in spontaneous and clomiphene citrate cycles. Fertil Steril1991;56:465-468.
35.
35. Gysler M, March C, Mishell DJ Jr, Bailey EJ. A decade's experience with an individualized clomiphene treatment regimen including its effects on the postcoital test. Fertil Steril1982;37:161-167.
36.
36. Gelety TJ, Buyalos RP. The effect of clomiphene citrate and menopausal gonadotropins on cervical mucus in ovulatory cycles. Fertil Steril1993;60:471-476.
37.
37. Hsu CC, Kuo HC, Wang ST, Huang KE. Interference with uterine blood flow by clomiphene citrate in women with unexplained infertility. Obstet Gynecol1995;86:917-921.
38.
38. Oktay K, Berkowitz P, Berkus M, Schneken RS, Brzyski RG. The re-incarnation of an old question—clomid effect on oocyte and embryo?Fertil Steril2000;74:422-423.
39.
39. Branigan EF, Estes MA. Minimal stimulation IVF using clomiphene citrate and oral contraceptive pill pretreatment for LH suppression. Fertil Steril2000;73:587-590.
40.
40. Zayed F. Outcome of stimulated in vitro fertilisation (SIVF) using clomiphene citrate and human menopausal gonadotropin in different infertility groups. Clin Exp Obstet Gynecol1999;26:227-229.
41.
41. Lu PY, Lee Sh, Chen ALJ, Erickson LD, Atkinson EJ, Ory SJ. Minimal stimulation achieves pregnancy rates comparable to human menopausal gonadotropins in the treatment of infertility. Fertil Steril1996;65:583-587.
42.
42. Dhaliwal LK, Sialy RK, Gopalan S, Majumdar S. Minimal stimulation protocol for use with intrauterine insemination in the treatment of infertility. J Obstet Gynaecol Res2002;28:295-299.
43.
43. Houmard BS, Juang MP, Soules MR, Fujimoto VY. Factors influencing pregnancy rates with a combined clomiphene citrate/gonadotropin protocol for non-assisted reproductive technology fertility treatment. Fertil Steril2002;77:384-386.
44.
44. Tomlinson MJ, Amissah-Aruthur JB, Thompson KA, Kasraie JI, Bentick B. Prognostic indicators for intrauterine insemination (IUI): statistical model for IUI success. Hum Reprod1996;11:1892-1896.
45.
45. Nuojua-Huttunen S, Tomas C, Bloigu R, Tuomivaara L, Martikainen H. Intrauterine insemination treatment in subfertility: An analysis of factors affecting outcome. Hum Reprod1999;14:698-703.
46.
46. van Hooff MH, Alberda AT, Huisman GJ, Zeilmaker GH, Leerentveld RA. Doubling the human menopausal gonadotrophin dose in the course of an in-vitro fertilization treatment cycle in low responders: A randomized study. Hum Reprod1993;8:369-373.
47.
47. Russell IB. Pre-cycle estrogen treatment and poor responders. Assist Reprod Rev1995;5:82-89.
48.
48. Dor J, Seidman DS, Amudai E, Bider D, Levran D, Mashiach S. Adjuvant growthhormone therapy in poor responders to in-vitro fertilization: A prospective randomized placebo- controlled double-blind study. Hum Reprod1995;10:40-43.
49.
49. Gonen Y, Jacobsen W, Casper RF. Gonadotropin suppression with oral contraceptives before in-vitro fertilization. Fertil Steril1990;53:282-287.
50.
50. Howles CM, Macnamee MC, Edwards RG. Short term use of an LHRH agonist to treatpoor responders entering an in-vitro fertilization programme. Hum Reprod1987;8:655-656.
51.
51. Sioufi A, Gauducheau N, Pineau V, et al. Absolute bioavailability of letrozole in healthy post-menopausal women. Biopharm Drug Dispos1997;18:779-789.
52.
52. Sioufi A, Sandrenan N, Godbillon J, et al. Comparative bioavailability of letrozole under fed and fasting conditions is 12 healthy subjects after a 25 mg single oral administration. Biopharm Drug Dispos1997;186:489-497.
53.
53. Roberts VJ, Barth S, El-Roeiy A, Yen SSC. Expression of inhibin/activin system messenger ribonucleic acids and proteins in ovarian follicles from women with polycystic ovarian syndrome. J Clin Endocrinol Metab1994;79:1434-1439.
54.
54. Yamoto M, Minami S, Nakano R. Immunohistochemical localization of inhibin subunits in polycystic ovary. J Clin Endocrinol Metab1993;77:859-862.
55.
55. Jaatinen T, Penttila T, Kaipia A, Ekfors T, Parvinen M, Toppari J. Expression of inhibin α, βA and βB messenger ribonucleic acids in the normal human ovary and in polycystic ovarian syndrome. J Endocrinol1994;143:127-137.
56.
56. Anderson RA, Groome NP, Baird DT. Inhibin A and inhibin B in women with polycystic ovarian syndrome during treatment with FSH to induce mono-ovulation. Clin Endocrinol Oxf1998;48:577-584.
57.
57. Lockwood GM, Muttukrishna S, Groome NP, Matthews DR, Ledger WL. Mid-follicular phase pulses of inhibin B are absent in polycystic ovarian syndrome and are initiated by successful laparoscopic ovarian diathermy: A possible mechanism regulating emergence of the dominant follicle. J Clin Endocrinol Metab1998;83:1730-1735.
58.
58. Weil SJ, Vendola K, Zhou J, et al. Androgen receptor gene expression in the primate ovary: Cellular localization, regulation, and functional correlations. J Clin Endocrinol Metab1998;837:2479-2485.
59.
59. Weil S, Vendola K, Zhou J, Bondy CA. Androgen and follicle-stimulating hormone interactions in primate ovarian follicle development. J Clin Endocrinol Metab1999;848:2951-2956.
60.
60. Vendola KA, Zhou J, Adesanya OO, Weil Sj, Bondy CA. Androgens stimulate early stages of follicular growth in the primate ovary. J Clin invest1998;10112:2622-2629.
61.
61. Vendola K, Zhou J, Wang J, Famuyiwa OA, Bievre M, Bondy CA. Androgens promote oocyte insulin-like growth factor I expression and initiation of follicle development in the primate ovary. Biol Reprod1999;612:353-357.
62.
62. Adashi E. Intraovarian regulation the proposed role of insulin-like growth factors. Ann NY Acad Sci1993;687:10-12.
64. Yen SSC, Laughlin GA, Morales AJ. Interface between extra-and intra-ovarian factors in polycystic ovary syndrome PCOS. Ann NY Acad Sci1993;687:98-111.
65.
65. Agarwal SK, Judd HL, Magoffin DA. A mechanism for the suppression of estrogen production in polycystic ovary syndrome. J Clin Endocrinol Metab1996;8110:3686-3691.
66.
66. Jakimiuk AJ, Weitsman Sr, Brzechffa PR, Magoffin DA. Aromatase mRNA expression in individual follicles from polycystic ovaries. Mol Hum Reprod1998;41:1-8.
67.
67. Laufer N, Pratt BM, DeCherney AH, et al. The in vivo and in vitro effects of clomiphene citrate on ovulation, fertilization, and development of cultured mouse oocytes. Am J Obstet Gynecol1983;147:633-639.
68.
68. Tanbo T, Dale PO, Lunde O, et al. Obstetric outcome in singleton pregnancies after assisted reproduction. Obstet Gynecol1995;86:188-192.
69.
69. Maman E, Lunenfeld E, Levy A, et al. Obstetric outcome of singleton pregnancies conceived by in vitro fertilization and ovulation induction compared with those conceived spontaneously. Fertil Steril1998;70:240-245.
70.
70. Hadi FH, Chantler E, Anderson E, et al. Ovulation induction and endometrial steroid receptors. Hum Reprod1994;9:2405-2410.
71.
71. Paulson RJ, Sauer MV, Lobo RA. Factors affecting embryo implantation after human in vitro fertilization: a hypothesis. Am J Obstet Gynecol1990;163:2020-2023.
72.
72. Simón C, Cano F, Valbueña D, et al. Clinical evidence for a detrimental effect on uterine receptivity of high serum ooestradiol concentrations in high and normal responder patients. Hum Reprod1995;10:2432-2437.
73.
73. Forman R, Fries N, Testart J, et al. Evidence for an adverse effect of elevated serum oestradiol concentration on embryo implantation. Fertil Steril1988;49:118-112.
74.
74. Garcia JE, Acosta AA, Hisu JG, Jones HWJ. Advanced endometrial maturation after ovulation induction with human menopausal gonadotrophin/human chorionic gonadotrophin for in vitro fertilization. Fertil Steril1984;41:31-35.
75.
75. Kolb BA, Najmabadi S, Paulson RJ. Ultrastructural characteristics of the luteal phase endometrium in patients undergoing controlled ovarian stimulation. Fertil Steril1997;67:625-630.
76.
76. Pellicer A, Ruiz A, Castellvi RM, et al. Is the retrieval of high-numbers ofoocytes desirable in patients treatedwith gonadotrophin-releasing hormone analogues (GnRHa) and gonadotrophins?Hum Reprod1989;4:536-540.
77.
77. Ertzeid G, Storeng R. Adverse effects of gonadotrophin treatment on pre- and postimplantation development in mice. J Reprod Fertil1992;96:649-655.
78.
78. Warner CM, Cao W, Exley GE, et al. Genetic regulation of egg and embryo survival. Hum Reprod1998;13Suppl 3:178-190.
79.
79. Kim HC, Kemmann E, Shelden RM, et al. Response of blood coagulation parameters to elevated endogenous 17 beta-oestradiol levels induced by human menopausal gonadotrophins. Am J Obstet Gynecol1981;140:807-810.
80.
80. Lox C, Canez M, DeLeon F, et al. Hyperestrogenism induced by menotropins alone or in conjunction with luprolide acetate in in vitro fertilization cycles: The impacton hemostasis. Fertil Steril1995;63:566-570.
81.
81. Van der Auwera I, Pijnenborg R, Koninckx PR. The influence of in-vitro culture versus stimulated and untreated oviductal environment on mouse embryo development and implantation. Hum Reprod1999;14:2570-2574.
82.
82. Mitwally MFM, Casper RF. Pregnancy outcome after the use of an aromatase inhibitor for ovarian stimulation. Fertil Steril2002;78(suppl 1):S277-S278.
